By Ahmed Aboulenein WASHINGTON, Feb 23 (Reuters) - U.S. Food and Drug Administration Commissioner Marty Makary on Monday ...

Commissioner Marty Makary defended his agency's position and record on mRNA vaccines, days after it changed course and agreed ...

Dr. Payal Kohli breaks down what this could mean for the next flu season and beyond.

In a sudden reversal, the US Food and Drug Administration has agreed to review Moderna’s experimental mRNA influenza vaccine.

Moderna Inc MRNA shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 while reiterating an Overweight rating. Here’s what you should know. Moderna ...

A single dose of mRNA-1073 elicited durable immune responses through 6 months against all vaccine-matched influenza and SARS-CoV-2 strains.

According to an FDA press release, the draft guidance "focuses on therapies that target a specific genetic, cellular, or molecular abnormality and are designed to correct or modify the underlying ...

By Arasu Kannagi Basil Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of ...

Sanofi and Bavarian Nordics are amongst the recipients of contracts that will run for around eight years to help bring new ...

Pfizer’s Albert Bourla put it more bluntly in Davos last month, saying it’s a “different world when you start discussing ...

Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.